Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/31949
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSILVA, Vanessa M.
dc.contributor.authorSCANAVACCA, Mauricio
dc.contributor.authorDARRIEUX, Francisco
dc.contributor.authorCAVALHEIRO, Cyrillo
dc.contributor.authorSTRUNZ, Celia C.
dc.date.accessioned2019-05-30T13:46:23Z
dc.date.available2019-05-30T13:46:23Z
dc.date.issued2019
dc.identifier.citationCLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, v.25, article ID UNSP 1076029619835053, 6p, 2019
dc.identifier.issn1076-0296
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/31949
dc.description.abstractDabigatran and rivaroxaban, direct oral anticoagulants (DOACs), affect coagulation tests, and knowledge of their effects is important for therapeutic monitoring. Our aim was to examine the association between DOAC levels and routine coagulation tests in patients with nonvalvular atrial fibrillation. Samples from patients receiving dabigatran (150 mg) and patients receiving rivaroxaban (20 mg) were collected 2 hours after drug intake. Direct oral anticoagulant concentrations were determined using direct Hemoclot thrombin inhibitor (HTI) assay (HTI test) and a direct Xa inhibitor (Anti Xa-Riva). The routine coagulation measured included activated partial thromboplastin time (aPTT) and prothrombin time (PT). The median plasmatic dabigatran was 128.3 ng/mL (95% confidence interval [CI]: 93.7-222.6 ng/mL). The HTI exhibited a good correlation with aPTT (R-2 = 0.74; P < .0001). The median plasmatic rivaroxaban was 223.9 ng/mL (95% CI: 212.3-238.9 ng/mL). Anti-Xa-Riva correlated with PT (R-2 = 0.69, P< .0001) and aPTT (R-2 = 0.36, P < .001), but prolonged PT results were obtained, even below the rivaroxaban therapeutic range (20%). The routine coagulation tests were able to identify out of therapeutic range concentrations for dabigatran and rivaroxaban. We suggest the use of these screening tests to better understand and monitor the subtherapeutic concentrations of these DOACs.eng
dc.language.isoeng
dc.publisherSAGE PUBLICATIONS INCeng
dc.relation.ispartofClinical and Applied Thrombosis-Hemostasis
dc.rightsopenAccesseng
dc.subjectdabigatraneng
dc.subjectrivaroxabaneng
dc.subjectprothrombin timeeng
dc.subjectactivated partial thromboplastin timeeng
dc.subject.otheranti-xa assayeng
dc.subject.otheranticoagulanteng
dc.subject.othervariabilityeng
dc.titleRoutine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy?eng
dc.typearticleeng
dc.rights.holderCopyright SAGE PUBLICATIONS INCeng
dc.identifier.doi10.1177/1076029619835053
dc.identifier.pmid30907118
dc.subject.wosHematologyeng
dc.subject.wosPeripheral Vascular Diseaseeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.description.articlenumberUNSP 1076029619835053
hcfmusp.description.volume25
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000462306000001
hcfmusp.origem.id2-s2.0-85063615824
hcfmusp.publisher.cityTHOUSAND OAKSeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceBaglin T, 2013, J THROMB HAEMOST, V11, P122, DOI 10.1111/jth.12227eng
hcfmusp.relation.referenceBaglin T., 2013, J THROMB HAEMOSTeng
hcfmusp.relation.referenceBaglin T, 2012, BRIT J HAEMATOL, V159, P427, DOI 10.1111/bjh.12052eng
hcfmusp.relation.referenceChan NC, 2015, J THROMB HAEMOST, V13, P353, DOI 10.1111/jth.12823eng
hcfmusp.relation.referenceCohen AT, 2018, INT J CARDIOL, V269, P174, DOI 10.1016/j.ijcard.2018.06.114eng
hcfmusp.relation.referenceColeman CI, 2018, HEART LUNG CIRC, V27, P390, DOI 10.1016/j.hlc.2017.04.002eng
hcfmusp.relation.referenceDager WE, 2012, ANN PHARMACOTHER, V46, P1627, DOI 10.1345/aph.1R179eng
hcfmusp.relation.referenceDouxfils J, 2013, THROMB HAEMOSTASIS, V110, P723, DOI 10.1160/TH13-04-0274eng
hcfmusp.relation.referenceDouxfils J, 2012, THROMB HAEMOSTASIS, V107, P985, DOI 10.1160/TH11-11-0804eng
hcfmusp.relation.referenceDyke CK, 2002, CIRCULATION, V105, P2385, DOI 10.1161/01.CIR.0000016351.12759.52eng
hcfmusp.relation.referenceEzekowitz MD, 2007, AM J CARDIOL, V100, P1419, DOI 10.1016/j.amjcard.2007.06.034eng
hcfmusp.relation.referenceGosselin RC, 2015, THROMB HAEMOSTASIS, V113, P77, DOI 10.1160/TH14-04-0361eng
hcfmusp.relation.referenceHawes EM, 2013, J THROMB HAEMOST, V11, P1493, DOI 10.1111/jth.12308eng
hcfmusp.relation.referenceHelin TA, 2013, CLIN CHEM, V59, P807, DOI 10.1373/clinchem.2012.198788eng
hcfmusp.relation.referenceHoxha A, 2017, AUTOIMMUN REV, V16, P173, DOI 10.1016/j.autrev.2016.12.010eng
hcfmusp.relation.referenceJanssen Pharmaceuticals Inc, XAR RIV PRESCR INFeng
hcfmusp.relation.referenceMueck W, 2011, CLIN PHARMACOKINET, V50, P675, DOI 10.2165/11595320-000000000-00000eng
hcfmusp.relation.referenceNielsen PB, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j510eng
hcfmusp.relation.referenceSamama MM, 2010, THROMB HAEMOSTASIS, V103, P815, DOI 10.1160/TH09-03-0176eng
hcfmusp.relation.referenceShimomura D, 2016, J CLIN LAB ANAL, V30, P941, DOI 10.1002/jcla.21960eng
hcfmusp.relation.referenceSholzberg M, 2018, JAMA-J AM MED ASSOC, V320, P1485, DOI 10.1001/jama.2018.13998eng
hcfmusp.relation.referencevan Ryn J, 2010, THROMB HAEMOSTASIS, V103, P1116, DOI 10.1160/TH09-11-0758eng
hcfmusp.relation.referenceYates SG, 2016, TRANSFUS APHER SCI, V55, P212, DOI 10.1016/j.transci.2016.06.005eng
hcfmusp.relation.referenceYOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1938-2723
hcfmusp.citation.scopus3-
hcfmusp.scopus.lastupdate2022-06-10-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor


Files in This Item:
File Description SizeFormat 
art_SILVA_Routine_Coagulation_Tests_in_Patients_With_Nonvalvular_Atrial_2019.PDFpublishedVersion (English)179.54 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.